Limits...
The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.

Kim YC, Kim JH, Cheung DY, Kim TH, Jun EJ, Oh JW, Kim CW, Chung WC, Kim BW, Kim SS, Kim JI, Park SH, Kim JK - Gut Liver (2015)

Bottom Line: For adenomatous lesions, the sensitivity of iM2-PK was 69.4%, which was also superior to iFOBT (12.1%, p<0.001).The iM2-PK exhibited increased sensitivity for identifying CRC and adenomatous lesions compared with iFOBT.Given its rapid results and convenience, CRC screening using iM2-PK is promising.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea.

ABSTRACT

Background/aims: M2 pyruvate kinase (M2-PK) is an enzyme that is produced in undifferentiated and proliferating tissues. This study aims to evaluate the usefulness of the immunochromatographic M2 pyruvate kinase (iM2-PK) for the screening of colorectal cancer (CRC) and premalignant lesions.

Methods: Healthy volunteers and patients with colorectal neoplasia were enrolled in six academic hospitals in the capital province of Korea. The iM2-PK value was compared with the immunochromatographic fecal occult blood test (iFOBT) and fecal tumor M2-PK enzyme-linked immunosorbent assay (ELISA).

Results: A total of 323 subjects were enrolled. The sensitivity of iM2-PK for CRC was 92.8%, which was superior to iFOBT (47.5%, p<0.0001). For adenomatous lesions, the sensitivity of iM2-PK was 69.4%, which was also superior to iFOBT (12.1%, p<0.001). Compared with M2-PK ELISA, iM2-PK exhibited significantly enhanced sensitivity for CRC (97.5% vs 80.0%, p=0.0289). The sensitivity of iM2-PK was higher in advanced stages of CRC compared with cancers confined to the mucosa and submucosa (p<0.05). However, lymph node metastasis had no influence on the sensitivity of iM2-PK.

Conclusions: The iM2-PK exhibited increased sensitivity for identifying CRC and adenomatous lesions compared with iFOBT. Given its rapid results and convenience, CRC screening using iM2-PK is promising.

No MeSH data available.


Related in: MedlinePlus

The receiver-operating characteristic curves for predicting adenoma (A) and colorectal cancer (B). Each line present receiver-operating characteristic curve for predicting adenoma and colorectal cancer by immunochromatographic M2 pyruvate kinase, immunochromatographic fecal occult blood test and carcinoembryonic antigen. All the curves are statistically significnt (p<0.001), with the areas beneath the curves being greater than 50%.iM2-PK, immunochromatographic M2 pyruvate kinase; AUC, area under the curve; iFOBT, immnochromatographic fecal occult blood test; CEA, carcinoembryonic antigen.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4562782&req=5

f1-gnl-09-641: The receiver-operating characteristic curves for predicting adenoma (A) and colorectal cancer (B). Each line present receiver-operating characteristic curve for predicting adenoma and colorectal cancer by immunochromatographic M2 pyruvate kinase, immunochromatographic fecal occult blood test and carcinoembryonic antigen. All the curves are statistically significnt (p<0.001), with the areas beneath the curves being greater than 50%.iM2-PK, immunochromatographic M2 pyruvate kinase; AUC, area under the curve; iFOBT, immnochromatographic fecal occult blood test; CEA, carcinoembryonic antigen.

Mentions: The receiver operating characteristic (ROC) curves of iM2-PK, iFOBT, and CEA for predicting patients with adenoma and CRC are shown in Fig. 1. The curves are statistically significant with the areas beneath them which are greater than 50%. The areas under the curves of iM2-PK are 0.88 for CRC and 0.76 for adenoma. These values are significantly higher than those of iFOBT and CEA (p<0.05). The threshold values of CEA, which were calculated as the most appropriate cutoff value using the ROC curve, were 1.28 U/mL for predicting adenoma and 3.14 U/mL for predicting CRC.


The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.

Kim YC, Kim JH, Cheung DY, Kim TH, Jun EJ, Oh JW, Kim CW, Chung WC, Kim BW, Kim SS, Kim JI, Park SH, Kim JK - Gut Liver (2015)

The receiver-operating characteristic curves for predicting adenoma (A) and colorectal cancer (B). Each line present receiver-operating characteristic curve for predicting adenoma and colorectal cancer by immunochromatographic M2 pyruvate kinase, immunochromatographic fecal occult blood test and carcinoembryonic antigen. All the curves are statistically significnt (p<0.001), with the areas beneath the curves being greater than 50%.iM2-PK, immunochromatographic M2 pyruvate kinase; AUC, area under the curve; iFOBT, immnochromatographic fecal occult blood test; CEA, carcinoembryonic antigen.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4562782&req=5

f1-gnl-09-641: The receiver-operating characteristic curves for predicting adenoma (A) and colorectal cancer (B). Each line present receiver-operating characteristic curve for predicting adenoma and colorectal cancer by immunochromatographic M2 pyruvate kinase, immunochromatographic fecal occult blood test and carcinoembryonic antigen. All the curves are statistically significnt (p<0.001), with the areas beneath the curves being greater than 50%.iM2-PK, immunochromatographic M2 pyruvate kinase; AUC, area under the curve; iFOBT, immnochromatographic fecal occult blood test; CEA, carcinoembryonic antigen.
Mentions: The receiver operating characteristic (ROC) curves of iM2-PK, iFOBT, and CEA for predicting patients with adenoma and CRC are shown in Fig. 1. The curves are statistically significant with the areas beneath them which are greater than 50%. The areas under the curves of iM2-PK are 0.88 for CRC and 0.76 for adenoma. These values are significantly higher than those of iFOBT and CEA (p<0.05). The threshold values of CEA, which were calculated as the most appropriate cutoff value using the ROC curve, were 1.28 U/mL for predicting adenoma and 3.14 U/mL for predicting CRC.

Bottom Line: For adenomatous lesions, the sensitivity of iM2-PK was 69.4%, which was also superior to iFOBT (12.1%, p<0.001).The iM2-PK exhibited increased sensitivity for identifying CRC and adenomatous lesions compared with iFOBT.Given its rapid results and convenience, CRC screening using iM2-PK is promising.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea.

ABSTRACT

Background/aims: M2 pyruvate kinase (M2-PK) is an enzyme that is produced in undifferentiated and proliferating tissues. This study aims to evaluate the usefulness of the immunochromatographic M2 pyruvate kinase (iM2-PK) for the screening of colorectal cancer (CRC) and premalignant lesions.

Methods: Healthy volunteers and patients with colorectal neoplasia were enrolled in six academic hospitals in the capital province of Korea. The iM2-PK value was compared with the immunochromatographic fecal occult blood test (iFOBT) and fecal tumor M2-PK enzyme-linked immunosorbent assay (ELISA).

Results: A total of 323 subjects were enrolled. The sensitivity of iM2-PK for CRC was 92.8%, which was superior to iFOBT (47.5%, p<0.0001). For adenomatous lesions, the sensitivity of iM2-PK was 69.4%, which was also superior to iFOBT (12.1%, p<0.001). Compared with M2-PK ELISA, iM2-PK exhibited significantly enhanced sensitivity for CRC (97.5% vs 80.0%, p=0.0289). The sensitivity of iM2-PK was higher in advanced stages of CRC compared with cancers confined to the mucosa and submucosa (p<0.05). However, lymph node metastasis had no influence on the sensitivity of iM2-PK.

Conclusions: The iM2-PK exhibited increased sensitivity for identifying CRC and adenomatous lesions compared with iFOBT. Given its rapid results and convenience, CRC screening using iM2-PK is promising.

No MeSH data available.


Related in: MedlinePlus